Description
A multi-kinase inhibitor; inhibits FLT3, CSF1R, c-Kit, FGFR1, FGFR3, VEGFR1, -2, and -3, PDFGRα, and PDGFRβ (IC50s = 1, 36, 2, 8, 9, 10, 13, 8, 27, and 210 nM, respectively); inhibits proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC50s = 90-550 and >2,500 nM, respectively); decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells at 500 nM; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice at 3-300 mg/kg for 8 days; reduces tumor growth in KM12L4A, DU145, and MV4-11 mouse xenograft models (ED50s = 17, 23, and 3 mg/kg per day, respectively)
Formal name: 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone
Synonyms: CHIR-258|TKI-258
Molecular weight: 392.4
CAS: 405169-16-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|FGFR Family||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling